New TB vaccines enter human trials – could they beat the world’s deadliest infection?

NCT ID NCT05547464

Ongoing ⭐️ VACCINE ⭐️ Sponsor: BioNTech SE Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests two experimental vaccines (BNT164a1 and BNT164b1) to see if they are safe and trigger an immune response against tuberculosis. About 500 healthy adults who have already received the BCG vaccine will receive three doses of either a vaccine or a placebo. The goal is to find the best dose for future larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TUBERCULOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

tuberculosis prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TUBERCULOSIS

Contacts and locations

Locations

Africa Health Research Institute (AHRI)

Mtubatuba, 3935, South Africa
CAPRISA eThekweni Clinical Research Site

Berea, 4001, South Africa
Centre for Lung Infection and Immunity UCT Lung Institute

Cape Town, 7700, South Africa
Centro de Investigação e Treino em Saúde da Polana Caniço (CISPOC) (recruiting participants for Part B only)

Maputo, 1102, Mozambique
Centro de Investigação em Saúde de Manhiça (CISM) (recruiting participants for Part B only)

Manhiça, 1929, Mozambique
Desmond Tutu Health Foundation - Masiphumele Research Office

Cape Town, 7975, South Africa
South African Tuberculosis Vaccine Initiative SATVI

Cape Town, 6850, South Africa
The Aurum Institute Tembisa CRC Clinic 4

Tembisa, 1632, South Africa

More trials for these conditions

Other studies related to the condition(s) this trial covers.